2024
Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions
Jacobs J, Booth G, Raza S, Clark L, Fasano R, Gavriilaki E, Abels E, Binns T, Duque M, McQuilten Z, Mingot‐Castellano M, Savani B, Sharma D, Tran M, Tormey C, Moise K, Bloch E, Adkins B. Current state and potential applications of neonatal Fc receptor (FcRn) inhibitors in hematologic conditions. American Journal Of Hematology 2024, 99: 2351-2366. PMID: 39324647, PMCID: PMC11560617, DOI: 10.1002/ajh.27487.Peer-Reviewed Original ResearchHematological conditionsFcRn inhibitorsClinical trialsStandardized treatment algorithmClinical trial dataNeonatal Fc receptorIn vivo studiesImmune-mediatedHematological disordersTreatment algorithmTransports IgGAdverse eventsImmunomodulatory/immunosuppressive therapiesIgG levelsPatient populationProtective IgGFc receptorsTherapeutic strategiesMucosal surfacesRheumatologic conditionsIgG antibodiesImmunoglobulin isotypesTrial dataIgGFcRn
2023
Passive transfer of alloantibodies through breast milk as a mediator of hemolytic anemia
Abels E, Jacobs J, Prior D, Willets L, Sostin N, Tormey C, Binns T. Passive transfer of alloantibodies through breast milk as a mediator of hemolytic anemia. Transfusion 2023, 63: 2188-2196. PMID: 37706556, DOI: 10.1111/trf.17548.Peer-Reviewed Original ResearchConceptsMaternal breast milkBreast milkNeonatal circulationRed blood cellsPassive transferAntiviral IgG antibodiesResolution of anemiaPaucity of dataNeonatal red blood cellsIntravenous immunoglobulinMaternal alloantibodiesMaternal antibodiesPlacental transferRBC antibodiesIgG antibodiesHemolytic diseaseHemolytic anemiaPlasma titersAlloantibodiesHDFNBlood cellsAntibodiesSignificant decreasePatientsAnemia